Analysis of the efficacy and side effects of pazopanib in the treatment of renal cell carcinoma

Pazopanib is an oral multi-target tyrosine kinase inhibitor that mainly acts on multiple targets including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-KIT). Due to its powerful anti-angiogenesis and anti-tumor proliferation effects, pazopanib is widely used in the treatment of advanced renal cell carcinoma (RCC), especially for patients who cannot undergo surgical resection or have postoperative recurrence, becoming a first-line or later-line targeted therapy option.

Clinical studies have shown that pazopanib has good efficacy in the treatment of patients with advanced renal cell carcinoma. Multiple key Phase III clinical trials have shown that pazopanib significantly prolongs patients' progression-free survival (PFS), usually to more than 8 months, while improving patients' quality of life. Compared with traditional chemotherapy, pazopanib has a more durable and stable effect on tumor control. After patients took it, the tumor shrinkage rate was obvious, some patients achieved partial remission, and some achieved disease stabilization, which significantly delayed the progression of the tumor.

Although pazopanib has significant efficacy, side effects are also an important aspect of clinical concern. Common side effects include high blood pressure, fatigue, diarrhea, abnormal liver function, hand-foot syndrome, and hypothyroidism. Hypertension is the most common side effect that requires active management. Patients need to regularly monitor blood pressure during treatment and undergo antihypertensive treatment as appropriate. Although liver function abnormalities are relatively rare, once they occur, drug dosage needs to be adjusted or discontinued promptly. In addition, hand-foot syndrome may affect the patient's daily life and needs to be alleviated through nursing and drug intervention.

During the actual medication process, patients need to use pazopanib rationally under the guidance of professional doctors, and undergo regular hematology and liver and kidney function monitoring to ensure medication safety and efficacy. Patients should pay attention to self-observation of adverse reactions and provide timely feedback to the doctor to avoid the occurrence of serious side effects. Overall, pazopanib has become an important targeted drug in the treatment of advanced renal cell carcinoma due to its good anti-tumor activity and controllable side effects, providing an effective guarantee for patients to extend their survival time and improve their quality of life.

References：https://www.votrient.com/